Goserelin EP Impurity I is a structurally related variant produced during goserelin synthesis. Differences in protecting-group removal or residue configuration influence retention time and secondary structure. Researchers employ it to validate sensitivity of analytical workflows. Applications include impurity profiling, stability studies, and peptide-route refinement.
CAT No: Z10-101-236
Synonyms/Alias:Endo-8a,8b-di-L-proline-goserelin; (S)-N-((6S,9S,12R,15S,18S,21S,24S)-21-((1H-Indol-3-yl)methyl)-1-amino-12-(tert-butoxymethyl)-6-((S)-2-((S)-2-((S)-2-(2-carbamoylhydrazine-1-carbonyl)pyrrolidine-1-carbonyl)pyrrolidine-1-carbonyl)pyrrolidine-1-carbonyl)-15-(4-hydroxybenzyl)-18-(hydroxymethyl)-25-(1H-imidazol-4-yl)-1-imino-9-isobutyl-8,11,14,17,20,23-hexaoxo-2,7,10,13,16,19,22-heptaazapentacosan-24-yl)-5-oxopyrrolidine-2-carboxamide;
Goserelin EP Impurity I is a chemically defined peptide impurity associated with the synthesis and quality assessment of goserelin, a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH). As a structurally related byproduct, this impurity emerges during the manufacturing or degradation of goserelin and is of significant interest in the context of peptide drug development, analytical method validation, and quality control. Its presence and characterization are critical for ensuring the integrity, efficacy, and safety of peptide-based pharmaceutical products, as well as for meeting stringent analytical standards in research and industrial environments.
Analytical method development: Goserelin-related impurities such as this compound play a vital role in the development and validation of high-performance liquid chromatography (HPLC), mass spectrometry, and other analytical methods. By serving as a reference standard, the impurity enables researchers to establish the sensitivity, specificity, and accuracy of detection techniques used to monitor peptide purity and identify trace contaminants in bulk drug substances and finished formulations. Its inclusion in analytical workflows helps laboratories meet regulatory expectations for impurity profiling and robust quality assurance.
Peptide synthesis optimization: The occurrence of Goserelin EP Impurity I during peptide manufacturing provides valuable insight into the synthetic process and potential degradation pathways. Investigating the formation of this impurity allows chemists to refine solid-phase peptide synthesis protocols, optimize reagent selection, and adjust reaction conditions to minimize byproduct generation. Such process improvements directly contribute to higher yields, improved product consistency, and reduced downstream purification requirements in industrial-scale peptide production.
Stability and degradation studies: The impurity serves as a key marker in forced degradation and stability-indicating studies, where it is used to monitor the chemical stability of goserelin under various environmental conditions. Tracking its formation over time enables scientists to identify degradation mechanisms, assess the impact of temperature, light, and pH, and establish appropriate storage and handling guidelines for peptide pharmaceuticals. These investigations are essential for determining shelf life and ensuring product reliability throughout the supply chain.
Quality control and batch release: In pharmaceutical manufacturing, the detection and quantification of process- and degradation-related impurities such as Goserelin EP Impurity I are integral to routine quality control and batch release testing. Its measurement supports compliance with pharmacopeial requirements and internal specifications, helping to verify that each lot of goserelin meets predefined purity criteria. Comprehensive impurity profiling not only safeguards product quality but also underpins regulatory submissions and continuous process verification efforts.
Peptide impurity research: Beyond its practical roles in manufacturing and analysis, the impurity is also utilized in academic and industrial research focused on peptide impurity characterization, structure-activity relationships, and the development of advanced purification technologies. Studying its physicochemical properties and interactions with chromatographic media contributes to a deeper understanding of peptide impurity behavior, informing the design of more selective and efficient separation strategies. Such research advances the broader field of peptide science and supports ongoing innovation in therapeutic peptide development.
1. Implications of ligand-receptor binding kinetics on GLP-1R signalling
5. Emu oil in combination with other active ingredients for treating skin imperfections
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More